United Capital Financial Advisors LLC Takes $654,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

United Capital Financial Advisors LLC acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,602 shares of the medical equipment provider’s stock, valued at approximately $654,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $204,000. Sivia Capital Partners LLC purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth $232,000. United Bank lifted its position in shares of Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after buying an additional 37,116 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $100.19 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $106.88. The stock has a market cap of $19.11 billion, a PE ratio of 24.38, a price-to-earnings-growth ratio of 2.74 and a beta of 0.45. The firm has a fifty day moving average price of $94.14 and a 200 day moving average price of $91.52.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the company posted $2.07 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Sanford C. Bernstein raised their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Zacks Research raised Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Royal Bank Of Canada boosted their target price on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Canaccord Genuity Group upped their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Finally, Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.